Schedule

Tuesday, Nov. 8, 2022

Pre-Conference Programs

Omni Boston Hotel at the Seaport

Times and program schedules subject to change.

Download Industry Program Schedule >

Combination Therapy: Using Novel Approaches to Identify Novel Biomarkers, Inform Patient Selection, and Design Trials

Omni Boston Hotel at the Seaport: 2–5:45 P.M. EST

Momentum Ballroom

no_symbol.pngIndicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.



SESSION I
 2–3:10 P.M. EST

Using Artificial Intelligence, Machine Learning, and/or Predictive Models to Identify Patients who will most likely Respond to Early Intervention
2 p.m. Introduction
Nicholas Botwood, MD – Bristol Myers Squibb

2:05 p.m. Radiomics, Pathomics, AI for Predicting and Monitoring Treatment Response for Cancer Therapies: Validation on Clinical Trial Datasets  
Anant Madabhushi, PhD – Emory University

2:25 p.m. no_symbol.pngLeaner, More Accurate Methods of Analyzing Therapeutic Efficacy
Antonio Tito Fojo, MD, PhD – Columbia University

2:45 p.m. Panel Discussion
Moderator: Nicholas Botwood, MD – Bristol Myers Squibb
Session I Speakers

3:10 p.m. Break


SESSION II
3:25–5:00 P.M. EST

Using Statistical Models to Refine and Optimize Clinical Trial Design

3:25 p.m. Introduction
Giovanni Melillo, MD – AstraZeneca

3:30 p.m. Adapting Radiotherapy to Immune Checkpoint Blockade
Silvia Formenti, MD – Weill Cornell Medicine
3:50 p.m. Adaptive Phase 2/3 Designs – Time to Hedge 
Cong Chen, PhD – Merck

4:10 p.m.
 no_symbol.pngSurrogate Endpoints and Patient Selection in Neoadjuvant Immunotherapy Trials: An Integrated Academia, Regulatory and Industry Effort
Tina Cascone, MD, PhD – The University of Texas MD Anderson Cancer Center 
4:30 p.m. Panel Discussion
Moderator: Giovanni Melillo, MD – AstraZeneca
Session II Speakers

5:00 p.m. Break


SESSION III
5:10–5:45 P.M. EST

Regulatory Considerations
5:10 p.m. no_symbol.pngIntroduction
Jane Anne Healy, MD – Merck

5:15 p.m. Assessment of Combination Therapies Regarding Safety, Dose, Contribution of Component 

Marc Theoret, MD – Food and Drug Administration (FDA)
5:40 p.m. no_symbol.pngConcluding Remarks
Jane Anne Healy, MD – Merck

Wednesday, Nov. 9, 2022

Pre-Conference Programs

Omni Boston Hotel at the Seaport

Times and program schedules subject to change.

Download Primer Program Schedule >   |  Download Workshop Schedule >   |  Download Grant Writing Workshop Schedule >

Primer on Tumor Immunology and Cancer Immunotherapy™ >   |   Meet the Expert Lunch >    |   Grant Writing Workshop >   |    Combination Therapy: Applying Learnings from Past Successes and Failures to Future Treatments >   |   Early Career Scientist Speed Mentoring Event >

Primer on Tumor Immunology and Cancer Immunotherapy™

Omni Boston Hotel at the Seaport: 8 A.M.–5 P.M. EST

Ensemble Ballroom

no_symbol.png Indicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.

SESSION I

8:05–9:45 A.M. EST

Introduction to Immunology: Generating Effective Anti-Tumor Immunity

8:05 a.m.

Overview of Innate Immunity in Cancer Immunotherapy and Complexities of Macrophages
Jennifer L. Guerriero, PhD – Brigham and Women’s Hospital
8:25 a.m. The Role of Dendritic Cells in Cancer
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
8:45 a.m. Modeling Adaptive Immune Responses to Cancer in the Mouse
Robert D. Schreiber, PhD, FAIO – Washington University School of Medicine

9:05 a.m. B cells and Tertiary Lymphoid Structures in Cancer: What are they Good for?
Tullia C. Bruno, PhD – University of Pittsburgh
9:25 a.m. Session I Panel Discussion
Moderator: Jennifer L. Guerriero, PhD – Brigham and Women's Hospital
Panelists: Session I Speakers

9:45 a.m.

Break

SESSION II

10–11:45 A.M. EST

Approaches to Immunotherapy: Targeting the Immunosuppressive Tumor Microenvironment
10 a.m. Targeting Tregs in Tumors
Dario A.A. Vignali, PhD – University of Pittsburgh

10:20 a.m. The Diversity, Function and Therapeutic Opportunities of Myeloid cells in Cancer
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai
10:40 a.m. Metabolism in Cancer Immunology and Immunotherapy
Greg M. Delgoffe, PhD – University of Pittsburgh
11 a.m. Tissue Tension Regulates Myeloid Metabolism to Modulate Tumor Immunity
Valerie M. Weaver, PhD – University of California, San Francisco
11:20 a.m. Session II Panel Discussion
Moderator: Jennifer L. Guerriero, PhD – Brigham and Women’s Hospital
Panelists: Session II Speakers

11:45 a.m.

Lunch

SESSION III
1:15–3 P.M. EST

Approaches to Immunotherapy: Driving T cells to the Tumor
1:15 p.m. no_symbol.pngIntroduction
Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center
1:20 p.m. Developing Personalized Cancer Vaccines
Catherine J. Wu, MD – Dana-Farber Cancer Institute and Harvard Medical School
1:40 p.m. Immune Checkpoint Blockade 
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center
2 p.m. Updates in the Science of CAR T cells
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
2:20 p.m. Modulating the Tumor Microenvironment with Bispecifics
Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center
2:40 p.m. Session III Panel Discussion
Moderator: Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center
Panelists: Session III Speakers
3 p.m. Break

SESSION IV
3:15–5 P.M. EST

Biomarkers of Response to Immunotherapies
3:15 p.m. The Role of the Gut and Tumor Microbiome in Cancer

Jennifer A. Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center
3:35 p.m. What You Need for a Good TIME (Tumor Immune MicroEnvironment)
James L. Gulley, MD, PhD – National Cancer Institute
3:55 p.m. no_symbol.pngImmune Biomarkers to Guide Clinical Care
Yvonne Saenger, MD – Albert Einstein College of Medicine
4:15 p.m. Current Practical Management and the Future of Personalized Treatment of Immune Related Adverse Events
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
4:35 p.m. Session IV Panel Discussion
Moderator: Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center
Panelists: Session IV Speakers
4:55 p.m. no_symbol.pngClosing Remarks
Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center

Combination Therapy: Applying Learnings from Past Successes and Failures to Future Treatments

Omni Boston Hotel at the Seaport: 9 A.M.–5:30 P.M. EST

Momentum Ballroom

no_symbol.png Indicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.

SESSION I
9–10:35 A.M. EST

Cellular Targets of Combination Therapies

  Moderator: Zhen Su, MD, MBA – Marengo Therapeutics
9 a.m. no_symbol.pngOverview
Daniel S. Chen, MD, PhD – Engenuity Life Sciences
9:10 a.m. no_symbol.pngRole of T cell Exhaustion Biology in Cancer Immunotherapy
E. John Wherry, PhD – University of Pennsylvania
9:40 a.m. no_symbol.pngCombination Myeloid cell and T cell Targeting as an Effective Anti-tumor Strategy
Judith A. Varner, PhD – University of California, San Diego
10:10 a.m. no_symbol.pngImplications of Cancer-Associated Fibroblast Heterogeneity for Stroma Targeted Therapies in Solid Tumors 
TBD
10:40 a.m. Break

SESSION II
10:45 A.M.–1:45 P.M. EST

Mediators of Immune Inhibition
  Moderator: Philip D. Greenberg, MD, FAIO – Fred Hutchinson Cancer Research Center
10:45 a.m.
no_symbol.pngSome Lessons from PD-L1/PD-1 Immunotherapy and Possibilities of New Pathways
Gordon J. Freeman, PhD, FAIO – Dana-Farber Cancer Institute
11:15 a.m. no_symbol.pngTGF-β Control of Immune Responses in Cancer: a Holistic Immuno-Oncology Perspective

Ming O. Li, PhD – Memorial Sloan Kettering Cancer Center
11:45 a.m. Lunch
1:15 p.m. no_symbol.pngCo-opting Immune cells to Support Cancer Progression through Metabolic Reprogramming
Susan M. Kaech, PhD – Salk Institute

SESSION III
1:45–3:15 P.M. EST

Immunotherapy Combination Strategies

  Moderator: Daniel S. Chen, MD, PhD – Engenuity Life Sciences
1:45 p.m. no_symbol.pngLearning from Failure to Identify New Strategies to Expand Checkpoint Blockade Efficacy
Thomas F. Gajewski, MD, PhD – University of Chicago
2:15 p.m. no_symbol.pngSynthetic Biology in the Age of Cell-Based Immunotherapy
Yvonne Chen, PhD – University of California, Los Angeles
2:45 p.m. no_symbol.pngRationalizing Orthogonal Combinations in Immunotherapy?
Ira Mellman, PhD – Genentech
3:15 p.m. Break

SESSION IV
3:25–5:30 P.M. EST

Immunotherapy Combination Trial Design
  Moderator: Alexandra Snyder, MD – Generate Biomedicines
3:25 p.m. no_symbol.pngApplication of New Approaches to Study IO Combinations
J. Carl Barrett, PhD – AstraZeneca

3:55 p.m. no_symbol.pngCombination Therapy - Lessons from Regulatory Submissions
Atiqur Rahman, PhD – Food and Drug Administration-CDER
4:25 p.m. Balancing Speed, Design and Regulatory needs to enable RP2D in Oncology 
Dinesh de Alwis, PhD – Merck Research Labs

4:55 p.m. no_symbol.pngRationale and Considerations for Designing Sequential Combination Approaches
Edward Cha, MD, PhD – Genentech
5:25 p.m.
no_symbol.pngConcluding Remarks
Alexandra Snyder, MD – Generate Biomedicines

Meet-the-Expert Lunch

Omni Boston Hotel at the Seaport: 11:45 A.M.–1:15 P.M. EST

Abstract Room
Contemporary Room
Deco Room
Modern Room


Grant Writing Workshop

Omni Boston Hotel at the Seaport: 5:45–7:50 P.M. EST

Marquee Room

no_symbol.png Indicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.

 

SESSION I

5:45–6:55 P.M. EST

GRANT WRITING WORKSHOP


Moderator: Ravi Patel, MD, PhD  – University of Pittsburgh

5:45 p.m.

no_symbol.pngOverview of Grant Opportunities Outside the NIH
Christian M. Capitini, MD – University of Wisconsin-Madison
5:55 p.m. NIH Grant Application Strategies
Lillian Kuo, PhD – National Cancer Institute

6:10 p.m. no_symbol.pngOptimizing your Strategy for Grant Writing
Thomas F. Gajewski, MD, PhD – University of Chicago
6:25 p.m. Principles of Data Sharing
Riyue Bao, PhD – UPMC Hillman Cancer Center

6:40 p.m. Question and Answer

SESSION II

6:55–7:50 P.M. EST

GRANT WRITING WORKSHOP

Moderator: Saman Maleki, PhD – Western University

6:55 p.m.

no_symbol.pngMock Study Section
Chair: Thomas F. Gajewski, MD, PhD – University of Chicago
Scientific Review Officer: Lillian Kuo, PhD – National Cancer Institute
Primary Reviewer: Christian M. Capitini, MD – University of Wisconsin-Madison
Secondary Reviewer: Ravi Patel, MD, PhD – University of Pittsburgh
Statistical Reviewer: Annette Molinaro, MA, PhD – University of California, San Francisco
7:30 p.m. no_symbol.pngQuestion and Answer Tables (Various Types of Grants) 
R01– Riyue Bao, PhD – UPMC Hillman Cancer Center and Lillian Kuo, PhD – National Cancer Institute
K08, K22, K99/R00, and other Career Development Awards – Kristin G. Anderson, PhD – Fred Hutchinson Cancer Research Center and Ravi Patel, MD, PhD – University of Pittsburgh
Foundation Young Investigator and Clinical Investigator Awards &
Fellowships and Career Development Awards for Clinicians – Abdul Rafeh Naqash, MD – Oklahoma University
Industry Funding: Clinical and Translational Trials – Christian M. Capitini, MD – University of Wisconsin-Madison and Saman Maleki, PhD – Western University

DOD Grants – Lorenzo Galluzzi, PhD – Weill Cornell Medicine and Claire I. Vanpouille-Box, PhD – Weill Cornell Medicine
F Grants for Graduate Students and Postdocs – Nicole E. Scharping, PhD – University of California San Diego
R01, Career Development and DOD Grants (Virtual Discussion) – Rongze "Olivia" Lu, PhD – University of California, San Francisco
7:45 p.m. no_symbol.pngConcluding Remarks
Rongze "Olivia" Lu, PhD – University of California, San Francisco

Early Career Scientist Speed Mentoring Event

Omni Boston Hotel at the Seaport: 8:00 P.M.–9:00 P.M. EST*


 

Thursday, Nov. 10, 2022

37th Annual Meeting

Boston Convention & Exhibition Center

9 a.m.–9 p.m. EST

Times and program schedules subject to change.

Download Annual Meeting Schedule >

no_symbol.png Indicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.

Session 100

7:40–8 A.M. EST

Presidential Welcome & Awards Ceremony

Location: Hall B2
Chair: Patrick Hwu, MD – Moffitt Cancer Center

 7:40 a.m.

 no_symbol.pngPresidential Welcome

Patrick Hwu, MD – Moffitt Cancer Center

7:45 a.m.

 no_symbol.pngAwards Ceremony 

Patrick Hwu, MD – Moffitt Cancer Center

  • Steven A. Rosenberg, MD, PhD, Scholars Award

  • SITC Fellow of the Academy of Immuno-Oncology (FAIO) Recipients Recognition

  • SITC Lifetime Achievement Award

Session 101

8–8:50 A.M. EST

Richard V. Smalley Memorial Award and Lectureship
A panel honoring the work of Zelig Eshhar, PhD, FAIO

Location: Hall B2
Chair: Patrick Hwu, MD – Moffitt Cancer Center
8 a.m. no_symbol.pngIntroduction and 2022 Richard V. Smalley Memorial Award and Lectureship Recognition

Patrick Hwu, MD – Moffitt Cancer Center
8:05 a.m. no_symbol.pngPanel Honoring the Work of Zelig Eshhar, PhD
Carl June, MD, FAIO – University of Pennsylvania
Crystal Mackall, MD – Stanford University
Steven A. Rosenberg, MD, PhD, FAIO – National Cancer Institute
Michel Sadelain, MD, PhD – Memorial Sloan Kettering Cancer Center
8:45 a.m. Question & Answer

8:50–8:55 a.m. EST

Break

Session 102

8:55–11:05 A.M. EST

Biomarkers

Location: Hall B2
Co-Chairs:
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai
Kerry L. Reynolds, MD – Massachusetts General Hospital
8:55 a.m. no_symbol.pngIntroduction
Kerry L. Reynolds, MD – Massachusetts General Hospital
9 a.m. no_symbol.pngCIMAC/SWOG Studies, Effort Funded for IO Biomarkers
Cara Haymaker, PhD – The University of Texas MD Anderson Cancer Center
9:20 a.m. no_symbol.pngMulti-omic Single-cell Discrimination of Immunotherapy-induced Immune Responses
Lawrence Fong, MD – University of California San Francisco
9:40 a.m. no_symbol.pngThe Androgen Receptor as a Gate Keeper for Effective Immunotherapy in Prostate Cancer
Amy E. Moran, PhD – Oregon Health & Science University
10 a.m.

no_symbol.pngImmune Related Adverse Events
Alexandra-Chloe Villani, PhD – Massachusetts General Hospital
10:20 a.m. no_symbol.png(635) KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer
Roy Herbst, MD, PhD – Yale Cancer Center, Yale School of Medicine
10:35 a.m. Panel Discussion
11 a.m. no_symbol.pngClosing Remarks
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

11:05–11:10 a.m. EST

Break

Session 103

11:10–11:40 A.M. EST

Late-Breaking Abstract Session

Location: Hall B2
Chair: Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

11:10 a.m.

(1478) A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells
Stefanie Mandl, PhD – PACT Pharma

11:25 a.m.

(1470) Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)
Wade T. Iams, MD – Vanderbilt University Medical Center

11:40 A.M.–1:10 P.M. EST

Lunch & Poster Viewing

Location: Hall C

Concurrent Session 104

11:55 A.M.–12:55 P.M. EST

Rapid Oral Abstracts - Basic Science

Location: Ballroom East
Co-Chairs:
Aitziber Buque Martinez, PhD – Weill Cornell Medicine
Aleksei Tikhonov, PhD – Gustave Roussy

11:55 a.m.

no_symbol.png(161) Single-cell spatial in situ transcriptomics unravels vulvar HSIL composition associated with complete response to therapeutic vaccination
Ziena Abdulrahman, MD, MS – Leiden University Medical Center, Oncode

12:03 p.m.

(511) T cell-instructed inflammation drives immune checkpoint inhibitor therapy resistance
Nam Woo Cho – Helen Diller Family Comprehensive Cancer Center, Parker Institute for Cancer Immunotherapy, Chan Zuckerberg Biohub, University of California, San Francisco

12:11 p.m.

(1224) Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer
Jashodeep Datta, MD – University of Miami Miller School of Medicine

12:19 p.m.

Question and Answer

12:25 p.m.

(123) Landscape analysis of the neoepitope-specific T cell responses in patients with and without clinical benefit from immune checkpoint blockade therapy
Cristina Puig Saus – University of California, Los Angeles

12:33 p.m.

no_symbol.png(408) Neutralizing oxidative damage at telomeres prevents T cell dysfunction and improves adoptive cell therapy
Dayana Rivadeneira, PhD – University of Pittsburgh

12:41 p.m.

(1140) Cancer stem cells and PD-L1-expresing exosomes suppress anti-tumor effector B cells
Qiao Li, PhD – University of Michigan

12:49 p.m.

Question and Answer

Concurrent Session 105

11:55 A.M.–12:55 P.M. EST

Rapid Oral Abstracts - Clinical

Location: Ballroom West
Co-chairs:
Praveen K. Bommareddy, MD, PhD – Replimune Inc.
Robyn Gartrell, MD, MS – Columbia University, New York Presbyterian

11:55 a.m.

(666) Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Roger Li, MD – H. Lee Moffitt Cancer Center & Research

12:03 p.m.

(642) EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1-2 EOGBM1-18/ROSALIE study
David Reardon, MD – Dana-Farber Cancer Institute

12:11 p.m.

(570) Cabozantinib plus atezolizumab in advanced head and neck cancer previously treated with platinum-containing chemotherapy: Results from Cohort 17 of the COSMIC-021 Study
Saad Kahn, MD – Stanford Cancer Institute and Stanford University

12:19 p.m.

Question and Answer

12:25 p.m.

no_symbol.png(374) Discovery of a public HPV16-E6 directed T cell response that is associated with overall and progression free survival
Nils-Petter Rudqvist, PhD – The University of Texas MD Anderson Cancer Center

12:33 p.m.

(789) Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study)
Amod A. Sarnaik, MD, FACS – H. Lee Moffitt Cancer Center & Research

12:41 p.m.

(1040) A population of ectoenzyme expressing T-cells with an immunosuppressive phenotype are associated with checkpoint immunotherapy resistance in metastatic melanoma patients
David Woods, PhD – University of Colorado School of Medicine

12:49 p.m.

Question and Answer

Concurrent Session 106

11:55 A.M.–12:55 P.M. EST

Integrating Radiation and Immunotherapy for the Treatment of Oligometastatic Disease

Location: 210ABC
Co-chairs:
Samir N. Khleif, MD - Georgetown University Medical Center
Andrew Sikora, MD, PhD - The University of Texas MD Anderson Cancer Center

11:55 a.m.

no_symbol.pngIntroduction
Samir N. Khleif, MD - Georgetown University Medical Center

12 p.m.

no_symbol.pngClinical Opportunities
Mai-Anh Huynh, MD, PhD - Harvard Medical School

12:10 p.m.

Current Challenges that Limit Immunotherapy and How These May Be Overcome by Integrating Radiation Therapy
Fernanda Herrera, MD, PhD - University of Lausanne

12:20 p.m.

Next-Generation Approaches to the Delivering Radiation in Conjunction with Immunotherapy for Patients with Oligometastatic Disease
Ravi Patel, MD, PhD – University of Pittsburgh

12:30 p.m.

no_symbol.pngFuture Directions in the Integration of Radiotherapy and Immunotherapy for Patients with Oligometastatic Disease
Zachary Morris, MD, PhD - University of Wisconsin - Madison

12:40 p.m.

Discussion and Conclusion

12:00–1:00 p.m. EST

Complimentary SITC Member Headshots

SITC Booth

12:30–1:00 p.m. EST

JITC Meet the Editor

SITC Booth

Session 107

1:10–2:55 P.M. EST

Immuno-oncology in the Age of Multi-omics: Translating Big Data into Clinical Discoveries

Location: Hall B2
Co-Chairs:
Kellie N. Smith, PhD – Johns Hopkins School of Medicine
Linghua Wang, MD, PhD – The University of Texas MD Anderson Cancer Center
1:10 p.m. no_symbol.pngMultiplex IF Big Data
Janis Taube, MD, MSc – Johns Hopkins School of Medicine
1:30 p.m. Integrative Big Data Approaches for Immuno-oncology
Aaron Newman, PhD - Stanford University

1:50 p.m. no_symbol.pngDiscovering the Rules of Human Tumor Immunity
Nir Hacohen, PhD - Massachusetts General Research Institute

2:10 p.m. (939) Augmentation of CD8 T cell memory via CDK4/6 inhibition can be sequentially combined with PD-1 blockade to avoid toxicities
Stephanie Dougan, PhD – Dana-Farber Cancer Institute
2:25 p.m. (50) Merkel cell polyomavirus-specific CD8 T cells in blood, but not in tumors, correlate with immunotherapy response in Merkel cell carcinoma
Thomas Pulliam – University of Washington
2:40 p.m. Panel Discussion

2:55–3:20 p.m. EST

Break

Session 1081

3:20–4:30 P.M. EST

Pre-Clinical/Model Systems vs. Human

Location: Hall B2
Co-Chairs:
Elizabeth M. Jaffee, MD, FAIO – Sidney Kimmel Cancer Center, Johns Hopkins University
Robert D. Schreiber, PhD – Washington University School of Medicine
3:20 p.m. no_symbol.pngIntroduction
Robert D. Schreiber, PhD – Washington University School of Medicine
3:25 p.m. no_symbol.pngCombination Vaccine + Checkpoint Immunotherapies
Elizabeth Jaffee, MD, FAIO - Sidney Kimmel Cancer Center, Johns Hopkins University
3:35 p.m. no_symbol.pngUse of High Dimensional Transcriptomic, Proteomic and Spatial Profiling in Mouse Tumor Models of Cancer Immunotherapy and the Applicability of These Studies to Understanding Naturally Occurring and Therapeutically Induced Human Responses to Cancer
Robert Schreiber, PhD, FAIO - Washington University School of Medicine
3:45 p.m. no_symbol.pngCellular Therapies
Philip Greenberg, MD, FAIO - Fred Hutchinson Cancer Research Center
3:55 p.m. no_symbol.pngMouse Models of Human Immune Tumor Microenvironments
Anthony Rongvaux, PhD – Fred Hutchinson Cancer Research Center
4:05 p.m. no_symbol.pngPanel Discussion

4:30–4:40 p.m. EST

Break

Concurrent Session 108

4:40–5:55 P.M. EST

Immune-Related Adverse Events: Current Status of Research and Paths Forward

Location: 210ABC
Co-Chairs:
Elad Sharon, MD, MPH – National Cancer Institute
Chloe Villani, PhD – Massachusetts General Hospital
4:40 p.m. no_symbol.pngOverview of Management of Rare Toxicities 
Kerry Reynolds, MD – Massachusetts General Hospital; Harvard Medical School
4:55 p.m. no_symbol.pngClinical Trials for Immune-Related Adverse Events
Michael Dougan, MD, PhD – Massachusetts General Hospital
5:10 p.m. no_symbol.pngImmune-Mediated Mechanisms in Checkpoint Inhibitor-Induced Myocarditis
Han Zhu, MD – Stanford University
5:25 p.m. (441) Checkpoint inhibitor-associated inflammatory arthritis is comprised of multiple clinical endotypes characterized by distinct transcriptional programs
Gary Reynolds, MBBS, PhD – Newcastle University, United Kingdom
5:37 p.m. Panel Discussion

Concurrent Session 109

4:40–5:55 P.M. EST

Advances in Imaging Biomarkers, Radiomics, and Artificial Intelligence

Location: 253ABC
Co-Chairs:
Pedram Heidari, MD – Massachusetts General Hospital
Bachir Taouli, MD – Icahn School of Medicine at Mount Sinai
4:40 p.m. no_symbol.pngImaging Response Criteria for Immunotherapy
Lilja Bjork Solnes, MD, MBA – Johns Hopkins Medicine
4:52 p.m. Introduction to Radiomics
Anant Madabhushi, PhD – Emory University
5:04 p.m. Radiomics Response to Immunotherapy
Jaileene Perez-Morales, PhD – Moffitt Cancer Center
5:16 p.m. no_symbol.pngNovel Molecular Imaging Approaches to Assess Immunotherapy Response
Umar Mahmood, MD, PhD – Massachusetts General Hospital
5:28 p.m. (1280) Radiomic and clinical prediction of overall and organ-specific response to ipilimumab-nivolumab in melanoma
Zane Gray – University of Pittsburgh
5:40 p.m. (1287) Radiomics and delta-radiomics signatures to predict response and survival in patient with non-small cell lung cancer treated with immune checkpoint inhibitors
Wim Vos, PhD – Radiomics
5:52 p.m. Closing Remarks

Concurrent Session 110

4:40–5:55 P.M. EST

Bias & Diversity in Cancer Research

Location: 258ABC
Co-Chairs:
Avery D. Posey, PhD – University of Pennsylvania School of Medicine
Cardinale Smith, MD, PhD – The Tisch Cancer Institute at Mount Sinai
4:40 p.m. no_symbol.pngIntroduction
Avery D. Posey, PhD – University of Pennsylvania School of Medicine
4:45 p.m. no_symbol.pngDiscuss Access to Immunotherapy Clinical Trials as Well as Community Outreach and Engagement Strategies to Engage Diverse Populations in Trials
Carmen Guerra, MD, MSCE, FACP - Perlman School of Medicine at the University of Pennsylvania
4:45 p.m. Barriers and Strategies to Increase Clinical Trial Diversity
Barbara Powe, PhD, RN, FAAP
4:45 p.m. no_symbol.pngMultilevel Interventions to Enhance Diversity in Oncology Clinical Trials
John H. Stewart, IV, MD, MBA, FACS - Louisiana State University
5:50 p.m. no_symbol.pngClosing Remarks
Cardinale Smith, MD, PhD – The Tisch Cancer Institute at Mount Sinai

Concurrent Session 111

4:40–5:55 P.M. EST

Organ-Specific Immune Responses

Location: 205ABC
Co-Chairs:
Amy B. Heimberger, MD – Northwestern University
Hélène Salmon, PhD – Icahn School of Medicine at Mount Sinai
4:40 p.m. no_symbol.pngIntroduction to the Field
Hélène Salmon, PhD – Icahn School of Medicine at Mount Sinai
4:50 p.m. no_symbol.pngMicrobiome within Pancreatic Tumors and Impact on Immune Microenvironment
Florencia McAllister, MD – MD Anderson Cancer Center
5:15 p.m. Regulation of Tissue Specific Immune Responses by Innate Lymphoid Cells
Jeremy Goc, PhD – Weill Cornell Medicine
5:40 p.m. (1052) Tissue-specific interferon-gamma drives regulatory T-cells to restrain DC1-mediated priming of cytotoxic T-cells against lung cancer
Maria Zagorulya, BS – MIT
5:55 p.m. Closing Remarks

Concurrent Session 112

4:40–5:55 P.M. EST

Cancer Immunogenomics and Immune Response

Location: Ballroom West
Co-Chairs:
Elaine Mardis, PhD – Nationwide Children's Hospital
Charles Swanton, MD, PhD, FRCP – University of London
4:40 p.m. no_symbol.pngFollow-on Studies on Adult GBM from Multi-Region Sequencing
Elaine Mardis, PhD – Nationwide Children's Hospital
5 p.m. no_symbol.pngGermline Immune Variants Influence Cancer Risk and Response to Immunotherapy
Hannah Carter, PhD – UC San Diego School of Medicine
5:20 p.m. Tumor-infiltrating B and Plasma Cells in Cancer Immunopathology and Immunotherapy Response
Linghua Wang, MD, PhD - MD Anderson Cancer Center
5:40 p.m. (956) Spatial clustering reveals immune hub interaction with reservoir of stem-like CD8 T cells and predicts immunotherapy response in lung cancer patients
Jonathan Chen, MD, PhD – Massachusetts General Hospital

Concurrent Session 113

4:40–5:55 P.M. EST

Cellular Therapies + Bispecifics

Location: Ballroom East
Co-Chairs:
Djordje Atanackovic, MD – University of Maryland Greenebaum Comprehensive Cancer Center
Yvonne Chen, PhD – University of California, Los Angeles
4:40 p.m. no_symbol.pngIntroduction
Djordje Atanackovic, MD – University of Maryland Greenebaum Comprehensive Cancer Center
4:42 p.m. Armored CAR NK Cells
Katy Rezvani, MD, PhD – MD Anderson Cancer Center
5:02 p.m. no_symbol.pngBispecific CAR-T Cell Therapies for Lymphoma
David Miklos, MD – Stanford University
5:22 p.m. no_symbol.pngHuman CD28 Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Targeting Non-Hodgkin lymphoma (NHL)
Dimitri Skokos, PhD – Regeneron Pharmaceuticals, Inc.
5:37 p.m. no_symbol.png(558) CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the Phase 1 COBALT-RCC study
Sumanta Pal, MD – City of Hope Comprehensive Cancer Center
5:52 p.m. no_symbol.pngClosing Remarks
Djordje Atanackovic, MD – University of Maryland Greenebaum Comprehensive Cancer Center

Concurrent Session 114

4:40–5:55 P.M. EST

Abstract Session

Location: Hall B2
Chair:
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center
4:40 p.m.

(505) High-dimensional analyses of intratumoral myeloid cells highlights presence of distinct myeloid cell phenotypes in immune checkpoint-sensitive and resistant tumors
Swetha Anandhan, MS – MD Anderson Cancer Center
4:55 p.m.

no_symbol.png(218) Immunogenic landscape and therapeutic targeting of mutant NRAS 'public' neoantigens
Inaki Etxeberria – Memorial Sloan Kettering Cancer Center (MSKCC)
5:10 p.m.

(237) Neoantigen-specific expansion of tumor-infiltrating lymphocytes enables effective treatment of p53-mutant cancer in mice
Peter Kim, PhD – NCI
5:25 p.m.

(1019) CSF1R+PD-L1+ tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin
Benjamin Ruf, MD – National Institutes of Health (NIH)
5:40 p.m.

no_symbol.png(1049) Reconstruction of gene regulatory networks dissects transcriptional control of intratumoral regulatory T cells
Feng Shan, MS – University of Pittsburgh

Concurrent Session 115

4:40–5:55 P.M. EST

Regulatory Subcommittee Session (Part 1)

Location: 153ABC
Co-Chairs:
Cecilia Yeung, MD – Fred Hutchinson Cancer Center
Alessandra Cesano, MD – ESSA Pharma

4:40 p.m.

no_symbol.pngFDA Talk on Project Optimus
Lola Fashoyin-Aje, MD, MPH – US Food and Drug Administration

4:50 p.m.

no_symbol.pngAcademic Biostatistician Talk on the impact of Project Optimus Recommendations on Rrial Statistics 
Mike LeBlanc, PhD – Fred Hutchinson Cancer Center

5 p.m.

no_symbol.pngFDA talk on their goals and thoughts regarding clinical trial subject diversity
Mirat Shah, MD – US Food and Drug Administration

5:10 p.m.

no_symbol.pngPanel Discussion
Cecilia Yeung, MD – Fred Hutchinson Cancer Center
Alessandra Cesano, MD – ESSA Pharma
Chantale Bernatchez, PhD – Cell Therapy Manufacturing Center
Lola Fashoyin-Aje, MD, MPH – US Food and Drug Administration
Bindu Kanapuru, MD – US Food and Drug Administration
Mike LeBlanc, PhD – Fred Hutchinson Cancer Center
Mirat Shah, MD – US Food and Drug Administration

5:55–6:05 p.m. EST

Break

Concurrent Session 116

6:05–7:20 P.M. EST

Cancer Immunotherapy in Special Patient Populations

Location: 253ABC
Co-Chairs:
Crystal Mackall, MD – Stanford University
Keith Sigel, MD, PhD - Icahn School of Medicine at Mount Sinai
6:05 p.m. no_symbol.pngImmunotherapy for Pediatric Cancer
Paul Sondel, MD, PhD – University of Wisconsin
6:25 p.m. no_symbol.pngImmunotherapy in Patients with HIV
Elizabeth Chiao, MD, MPH - MD Anderson Cancer Center
6:45 p.m. no_symbol.pngImmunotherapy in Patients with Autoimmune Diseases
Elad Sharon, MD, MPH – National Cancer Institute
7:05 p.m. (437) Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium
Talal El Zarif – Dana Farber Cancer Institute

Concurrent Session 117

6:05–7:20 P.M. EST

Targeting the Tumor and the Immune System: New Combinatorial Strategies

Location: Ballroom West

Co-Chairs:
Sandra Demaria, MD – Weill Cornell Medicine
Raghu Kalluri, MD, PhD – University of Texas MD Anderson Cancer Center
6:05 p.m. no_symbol.pngThe Biology and Function of Exosomes in Immune Regulation and Immunotherapy
Raghu Kalluri, MD, PhD – The University of Texas MD Anderson Cancer Center
6:25 p.m. no_symbol.pngCombinations of Chemotherapy and Targeted Agents with IT in Breast Cancer
Sherene Loi, MD, PhD - Peter MacCallum Cancer Centre
6:45 p.m. Rational Selection of Immunotherapy and Radiation Therapy Combinations
Sandra Demaria, MD - Weill Cornell Medicine
7:05 p.m. (915) Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 blockade therapy in small cell lung cancer
Evelyn Nguyen – Memorial Sloan Kettering Cancer Center

Concurrent Session 118

6:05–7:20 P.M. EST

Microbiome, Diet, and Cancer Immunotherapy

Location: Ballroom East
Co-Chairs:
Thomas F. Gajewski, MD, PhD – University of Chicago
Jennifer L. McQuade, MD – University of Texas MD Anderson Cancer Center
6:05 p.m. no_symbol.pngGut Microbiota Influence on Anti-tumor Immunity Via Regulation of Myeloid Cells 
Thomas Gajewski, MD, PhD – University of Chicago
6:25 p.m. no_symbol.pngDiet, the Microbiome and Immunotherapy Response: From Observation to Intervention
Jennifer McQuade, MD – University of Texas MD Anderson Cancer Center
6:45 p.m. no_symbol.pngFecal Microbiota Transplantation and Cancer Immunotherapy
Gal Markel, MD – Rabin Medical Center, Israel
7:05 p.m. no_symbol.png(1310) Dietary tryptophan catabolite released by intratumoral Lactobacillus reuteri facilitates anti-PD-L1 therapy
Alex McPherson, BSc – University of Pittsburgh

Concurrent Session 119

6:05–7:20 P.M. EST

Vaccines: in Situ Agents and Novel Systemic Approaches

Location: 205ABC
Co-Chairs:
Ann W. Silk, MD, MS – Dana-Farber Cancer Institute
Dmitry Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center
6:05 p.m. no_symbol.pngIntroduction
Ann W. Silk, MD, MS – Dana-Farber Cancer Institute
6:10 p.m. no_symbol.pngOncolytic Viral Therapy - Beyond the 1st Generation
Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center
6:25 p.m. no_symbol.pngUtilizing Tumor Microenvironment Antigens for Immune Modulatory Vaccines
Mads Hald Andersen, PhD – Herlev and Gentofte Hospital
6:40 p.m. (693) Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab as second-line (2L) treatment for advanced hepatocellular carcinoma (HCC)
Edward J. Gane, MD – The University of Auckland
6:50 p.m. no_symbol.png(595) Flt3L-primed in situ vaccination and pembrolizumab induce systemic tumor regressions of bulky tumors in patients with lymphomas and ER/PR+ breast cancer
Thomas Marron, MD, PhD – Icahn School of Medicine at Mount Sinai
7 p.m. no_symbol.png(615) Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (r/r) melanoma
Alexander Shoushtari, MD – Memorial Sloan Kettering Cancer Center
7:10 p.m. Panel Discussion

Concurrent Session 120

6:05–7:20 P.M. EST

Tertiary Lymphoid Structures

Location: 210ABC
Co-Chairs:
Haydn Kissick, PhD – Emory University
Catherine Sautes-Fridman, PhD – Centre de Recherche des Cordeliers
6:05 p.m. no_symbol.pngRecent Breakthroughs in TLS Field 
Catherine Sautes- Fridman, PhD – Centre de Recherche des Cordeliers
6:15 p.m. no_symbol.pngCellular Composition of TCF1+ CD8 T-cell Immune Neighborhoods in Human Cancers
Haydn Kissick, PhD – Emory University
6:25 p.m. no_symbol.pngCellular and Molecular Mechanisms Driving Development of Tertiary Lymphoid Structures in Cancer
Victor Engelhard, PhD – University of Virginia
6:45 p.m. Multifaceted Anti-tumor Effects of Intra-tumoral Tertiary Lymphoid Structures are Driven by Tfh Cells
Jose Conejo-Garcia, MD, PhD – Moffitt Cancer Center
7:05 p.m. (507) High endothelial venules control the journey of stem-like CD8+ T cells from lymph node to tumor during cancer immunotherapy with combined anti-PD-1 plus anti-CTLA-4 antibodies
Lucas Blanchard, MS – CNRS-IPBS, University of Toulouse

Concurrent Session 121

6:05–7:20 P.M. EST

Clinical Development of Novel Checkpoint Inhibitors

Location: 258ABC
Co-Chairs:
Hussein A. Tawbi, MD, PhD – The University of Texas MD Anderson Cancer Center
Hassane M. Zarour, MD – UPMC Hillman Cancer Center
6:05 p.m. no_symbol.pngIntroduction
Hassane M. Zarour, MD – UPMC Hillman Cancer Center
6:10 p.m. no_symbol.pngThe Emergence of LAG3-Blockade & Opportunities for Future Development
Hussein A. Tawbi, MD, PhD – The University of Texas MD Anderson Cancer Center
6:30 p.m. no_symbol.png(594) Dose escalation of next generation Anti-CTLA-4 antibody ONC-392 in combination with fixed dose of pembrolizumab in patients with advanced solid tumors  
Siwen Hu-Lieskovan, MD, PhD – Huntsman Cancer Institute, University of Utah
6:45 p.m. no_symbol.png(659) COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases
Michael Overman, MD – University of Texas MD Anderson Cancer Center
7 p.m. (605) Neoadjuvant vidutolimod (Vidu) and nivolumab (Nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results
Diwakar Davar, MD – UPMC Hillman Cancer Center
7:15 p.m. no_symbol.pngClosing Remarks
Hussein A. Tawbi, MD, PhD – The University of Texas MD Anderson Cancer Center

Concurrent Session 122

6:05–7:20 P.M. EST

Abstract Session

Location: Hall B2
Chair:
Tina Cascone, MD, PhD – The University of Texas MD Anderson Cancer Center
6:05 p.m.

(877) Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression
Sofia Bruni, MS – Instituto de Biologia y Medicina Experimental (IBYME-CONICET)
6:20 p.m.

(109) Quantitative spatial assessment of the tumor-immune microenvironment in the metastatic melanoma lymph node
Rachel Maus, PhD – Mayo Clinic
6:35 p.m.

(782) Intratumoral sotigalimab with pembrolizumab activates antigen-presenting cells and induces local and distant anti-tumor responses in first-line metastatic melanoma: Results of a phase I/II study
Salah-Eddine Bentebibel, PhD – The University of Texas MD Anderson Cancer Center
6:50 p.m.

Addition of IL-2 overcomes lung tumor resistance to IL-12 by coordinating cytotoxic and regulatory T cell responses
Brendan L. Horton, PhD – Massachusetts Institute of Technology
7:05 p.m.

(1403) Outcomes following first-line immunotherapy with or without chemotherapy stratified by KRAS mutational status - A real world analysis in patients with advanced NSCLC
Jyoti Patel – Robert H Lurie Comprehensive Cancer Center

Concurrent Session 123

6:05–7:20 P.M. EST

Regulatory Subcommittee Session (Part 2)

Location: 153ABC
Co-Chairs:
Cecilia Yeung, MD – Fred Hutchinson Cancer Center
Alessandra Cesano, MD – ESSA Pharma

6:05 p.m.

 no_symbol.pngOpening Remarks
Cecilia Yeung, MD – Fred Hutchinson Cancer Center

6:10 p.m.

 no_symbol.pngOverview of FDA Draft Guidance Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial
Peter Bross, MD – US Food and Drug Administration

6:20 p.m.

 An Industry Perspective on Iterative Manufacturing Processes for Cellular Therapies
John Langowski, PhD – Kite Pharma

6:30 p.m.

 An Academic Perspective on Iterative Manufacturing Processes for Cellular Therapies
Yen-Michael Hsu, MD, PhD – University of Pittsburgh Medical Center

6:40 p.m.

 no_symbol.pngPanel Discussion
Alessandra Cesano, MD – ESSA Pharma 
Cecilia Yeung, MD – Fred Hutchinson Cancer Center
Daniel Cushing, PhD – Carisma Therapeutics
Chantale Bernatchez, PhD –Cell Therapy Manufacturing Center
Peter Bross, MD – US Food and Drug Administration
John Langowski, PhD – Kite Pharma
Yen-Michael Hsu, MD, PhD – University of Pittsburgh Medical Center

7:20-7:30 p.m. EST

Break

7:30–8:15 P.M. ET (FAIO Event)
7:30–9 P.M. (Poster Viewing)

Poster Reception and Meet the Fellows (FAIO) Event

Location: Reception area by the Entrance inside Hall C (BCEC)

Friday, Nov. 11, 2022

37th Annual Meeting

Boston Convention & Exhibition Center

9 a.m.–8:30 p.m. EST

Times and program schedules subject to change.

Download Annual Meeting Schedule >

no_symbol.png Indicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.

Session 200

7:15–7:45 A.M. EST

Session 200: Business Meeting & Presidential Transition

Location: Hall B2

Session 201

8–8:20 A.M. EST

Organizer Welcome & Awards Ceremony

Location: Hall B2
Chair:
Patrick Hwu, MD – Moffitt Cancer Center
8 a.m. no_symbol.pngOrganizer Welcome
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

8:05 a.m.

no_symbol.pngAwards Ceremony
Patrick Hwu, MD – Moffitt Cancer Center

  • Tara Withington Public Service Award

  • Pedro J. Romero Service to JITC Award

  • JITC Best Paper Awards

Session 202

8:20–9:10 A.M. EST

Keynote Address

Location: Hall B2
Chair:
Patrick Hwu, MD – Moffitt Cancer Center
8:20 a.m. no_symbol.pngIntroduction
Patrick Hwu, MD – Moffitt Cancer Center
8:25 a.m. no_symbol.pngFrom the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
9:05 a.m. no_symbol.pngQuestion & Answer
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

9:10–9:35 a.m. EST

Break

Session 203

9:35–11:20 A.M. EST

Immunotherapy in Early Stage Disease

Location: Hall B2
Co-Chairs:
Matthew D. Galsky, MD – Tisch Cancer Institute At Mount Sinai Medical Center (GU)
Elizabeth A. Mittendorf, MD, PhD – Dana-Farber Cancer Institute Brigham & Women's Cancer Institute
9:35 a.m. no_symbol.pngWhy the Neoadjuvant Setting?
Myriam Chalabi, MD –The Netherlands Cancer Institute
10 a.m. no_symbol.pngNeoadjuvant Studies to Dissect Mechanisms Underlying Treatment Response and Resistance 
Tina Cascone, MD, PhD – The University of Texas MD Anderson Cancer Center
10:25 a.m. no_symbol.pngPathologic Assessment of Tissues, Planning of Treatments, Histopathology
Janis Taube, MD, MSc – Johns Hopkins School of Medicine
10:50 a.m. no_symbol.png(57) CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy
Tricia Cottrell, MD, PhD – Queen's University
11:05 a.m. (644) Major pathologic response after a single radiotherapy fraction + a single pembrolizumab dose given preoperatively in patients with cT1N0 triple negative breast cancer (TNBC) - preliminary results of a phase 1b/2 study (NCT04454528)
Julia Tchou, MD, PhD – University of Pennsylvania

11:20–11:25 a.m. EST

Break

Session 204

11:25–11:55 A.M. EST

Late-Breaking Abstract Session

Location: Hall B2
Chair:
Ryan J. Sullivan, MD – Massachusetts General Hospital

11:25 a.m.

(1477) First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma 
Patrick Y. Wen, MD – Dana Farber Cancer Institute

11:40 a.m.

(1472) Assessing the correlation between CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy
Michel Postow, MD – Memorial Sloan Kettering Cancer Center

11:55 A.M.-1:25 P.M. EST

Lunch & Poster Viewing

Location: Hall C

Concurrent Session 205

12:10–1:10 P.M. EST

Rapid Oral Abstracts – Basic Science

Location: Ballroom East
Co-Chairs: 
Kristin Anderson, PhD – Fred Hutchinson Cancer Research Center
Nicole E. Scharping, PhD – University of California San Diego

12:10 p.m.

(205) Specific AMPK agonism during CART in vitro expansion enhances oxidative metabolism and improves in vivo leukemia clearance  
Erica Braverman, MD – University of Pittsburgh

12:18 p.m.

(148) TAP2 deficiency mediates adaptive immune evasion and immunotherapy resistance in human non-small cell lung cancer
Kishu Ranjan, PhD – Yale University School of Medicine

12:26 p.m.

(1144) IL17-producing γδ T cells promote resistance to CDK4/6 inhibitors in HR+HER2- breast cancer  
Lorenzo Galluzzi, PhD – Weill Cornell Medicine

12:34 p.m.

Question and Answer

12:40 p.m.

no_symbol.png(951) Spatial atlases of immunological development within the lymph node
Tyler Hether, PhD – NanoString Technologies, Inc.

12:48 p.m.

(324) Sensitizing poorly differentiated thyroid cancers to TSHR-CART cell therapy with MEK inhibitors
Claudia Manriquez Roman – Mayo Clinic

12:56 p.m.

(868) CD122-directed IL-2/anti-IL-2 complexes massively expand stem-like tumor-specific T cells and enhance abscopal responses to radiation and anti-PD-1
Kateryna Onyshchenko – University Hospital Freiburg

1:04 p.m.

Question and Answer

Concurrent Session 206

12:10–1:10 P.M. EST

Rapid Oral Abstracts – Clinical

Location: Ballroom West
Co-Chairs: 
Lorenzo Falchi, MD – Memorial Sloan Kettering Cancer Center
Ravi Patel, MD, PhD – University of Pittsburgh

12:10 p.m.

(790) Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administ  
Jens Tijtgat, MD – UZ Brussel

12:18 p.m.

(315) Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508
Michael Ball, PhD – Carisma Therapeutics

12:26 p.m.

(763) Phase 1/2 dose escalation and dose expansion study of TransCon TLR7/8 agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumor malignancies: initial results from dose escalation 
Diwakar Davar, MBBS, MSc – University of Pittsburgh Medical Center

12:34 p.m.

Question and Answer

12:40 p.m.

(244) AFNT-111, a safe and effective TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V mutation
Hubert Lam, PhD – Affini-T Therapeutics

12:48 p.m.

(614) Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients
Saman Maleki, PhD – Western University

12:56 p.m.

(337) Development of potent iPSC-derived macrophages (iMACs) for off-the-shelf cancer immunotherapy – a new cell type in the EVOcells platform
Nadja Wagner – Evotec International GmbH

1:04 p.m.

Question and Answer

Concurrent Session 207

12:10–1:10 P.M. EST

A Look at JITC's High-Impact Science

Location: 205ABC
Co-Chairs:
James L. Gulley, MD, PhD, FACP – National Cancer Institute
Pedro J. Romero, MD – Lausanne Branch, Ludwig Institute for Cancer Research

 12:10 p.m.

no_symbol.pngIntroduction
Pedro J. Romero, MD – Lausanne Branch, Ludwig Institute for Cancer Research

 12:15 p.m.

no_symbol.pngUnderstanding Journal and Article Metrics: How to Valuate Them
Pedro J. Romero, MD – Lausanne Branch, Ludwig Institute for Cancer Research

 12:20 p.m.

no_symbol.pngHeterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
Pedro J. Romero, MD – Lausanne Branch, Ludwig Institute for Cancer Research

 12:25 p.m.

Acute kidney injury in patients treated with immune checkpoint inhibitors
Shruti Gupta, MD – Brigham and Women's Hospital

 12:30 p.m.

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
Marissa Herrman, PhD – Adicet Bio, Inc.

 12:35 p.m.

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
Monika Semmrich, PhD – BioInvent International AB

 12:40 p.m.

no_symbol.pngGut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
Pedro J. Romero, MD – Lausanne Branch, Ludwig Institute for Cancer Research

 12:45 p.m.

no_symbol.pngJITC: The Next 10 Years
James L. Gulley, MD, PhD, FACP – National Cancer Institute

 12:55 p.m.

Question and Answer

12:15–1:15 p.m. EST

Complimentary SITC Member Headshots

SITC Booth

Session 208

1:25–2:50 P.M. EST

Presidential Session

Location: Hall B2
Chair:
Patrick Hwu, MD – Moffitt Cancer Center

1:25 p.m.

no_symbol.pngIntroduction
Patrick Hwu, MD – Moffitt Cancer Center

1:30 p.m.

(590) Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers
Manoj Chelvanambi, PhD – The University of Texas MD Anderson Cancer Center

1:45 p.m.

(541) Intratumoral mregDC and T helper niches enable local reinvigoration of CD8 T cells following PD-1 blockade
Assaf Magen, PhD – Icahn School of Medicine at Mount Sinai

2 p.m.

no_symbol.pngExpert Discussant
Thomas F. Gajewski, MD, PhD – University of Chicago

2:10 p.m.

(1305) Impact of Tet2-mutant clonal hematopoiesis on solid tumor immunology and response to checkpoint blockade
Shelley Herbrich, PhD – The University of Texas MD Anderson Cancer Center

2:25 p.m.

(965) Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway to generate TCF1+ progenitor CD8 T cells to improve efficacy of PD-1 checkpoint blockade
Geoffrey Markowitz, PhD – Weill Cornell Medicine

2:40 p.m.

no_symbol.pngExpert Discussant
Niroshana Anandasabapathy, MD, PhD, FAAD – Weill Cornell Medicine

2:50–2:55 p.m. EST

Break

Session 209

2:55–4:05 P.M. EST

Survival Data in Adjuvant Setting; Analysis of Benefits (Debate)

Location: Hall B2
Co-Chairs:
Caroline Robert, MD, PhD – Institut Gustave Roussy
Thomas Powles, MBBS, MD, MRCP – Queen Mary University of London

2:55 p.m.

no_symbol.pngAdjuvant Therapy in Melanoma
Caroline Robert, MD PhD – Institut Gustave Roussy

3:02 p.m.

no_symbol.pngAdjuvant Therapy in Renal and Bladder Cancers
Bradley McGregor, MD – Dana-Farber Cancer Institute

3:09 p.m.

no_symbol.pngAdjuvant Therapy in Breast Cancer
Elizabeth A. Mittendorf, MD, PhD – Dana-Farber Cancer Institute Brigham & Women's Cancer Institute

3:16 p.m.

no_symbol.pngNeoadjuvant vs Adjuvant Immunotherapy for Resectable NSCLC
John Heymach, MD, PhD – University of Texas MD Anderson Cancer Center

3:23 p.m.

no_symbol.pngNeoadjuvant Therapy in GI Cancer
John Haanen, MD, PhD – Netherlands Cancer Institute

3:33 p.m.

no_symbol.pngQuestion and Answer
Moderator: Paul B. Chapman, MD – Memorial Sloan Kettering Cancer Center 

3:48 p.m.

no_symbol.pngDebate for and Against Adjuvant Therapy

4:05–4:20 p.m. EST

Break

Concurrent Session 210

4:20–5:35 P.M. EST

Cancer Surgery in the Age of immunotherapy

Location: Ballroom East
Co-Chairs:
Genevieve M. Boland, MD, PhD – Massachusetts General Hospital
Myron E. Schwartz, MD – Mount Sinai School of Medicine
4:20 p.m. Integrating Imaging and Tissue-Based Analysis to Unravel Treatment Response and Resistance Mechanisms in Melanoma
Ashley Holder, MD – University of Alabama at Birmingham
4:40 p.m. no_symbol.pngThe Expanding Role of Surgery in Stage IV Melanoma
Michael Lowe, MD, MA – Emory University School of Medicine
5 p.m. no_symbol.pngNeoadjuvant program –Surgeon’s Perspective Integration of Radiation in Neoadjuvant Therapy
John Sfakianos, MD – Icahn School of Medicine at Mount Sinai
5:20 p.m. no_symbol.png(613) Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma
Brian Olson, PhD – Emory University

Concurrent Session 211

4:20–5:35 P.M. EST

Extended Analysis of the Tumor Microenvironment: Beyond Tumor and Immune Cells

Location: Ballroom West
Co-Chairs:
Peter S. Nelson, MD – Fred Hutchinson Cancer Research Center
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine
4:20 p.m. no_symbol.pngTechnology Development; Spatial Imaging
Peter Sorger, PhD – Harvard Medical School
4:40 p.m. no_symbol.pngSenescent Cells in the TME
Jennifer Elisseeff, PhD – Johns Hopkins School of Medicine
5 p.m. Lymphatic Transport, Lymph Node Metastasis, and Immunity
Amanda Lund, PhD – NYU Grossman School of Medicine
5:20 p.m. (133) Spatially defined gene signatures uncover the association of extracellular matrix genes with immunotherapy resistance in head and neck squamous cell carcinoma
Niki Gavrielatou, MD – Yale School of Medicine

Concurrent Session 212

4:20–5:35 P.M. EST

Next Generation Checkpoint Blockade: Mechanisms of Action

Location: 205ABC
Co-Chairs:
Ana Carrizosa Anderson, PhD – Harvard Medical School
Ira Mellman, PhD – Genentech
4:20 p.m. no_symbol.pngTemporal Single-cell Profiling Identifies B-cell Specific Checkpoint Molecules that Regulate Anti-tumor Immunity
Vijay Kuchroo, DVM, PhD – Harvard Medical School
4:40 p.m. no_symbol.pngMechanisms of Tim-3 Inhibition
Ana Carrizosa Anderson, PhD - Harvard Medical School
5 p.m. no_symbol.pngTIGIT Mechanism of Action
Ira Mellman, PhD - Genentech
5:20 p.m. (504) PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion
Eran Ophir, PhD – Compugen Ltd.

Concurrent Session 213

4:20–5:35 P.M. EST

Next-Generation Cytokine Therapy

Location: 210ABC
Co-Chairs:
Kim A. Margolin, MD – St. John’s Cancer Institute
Aaron M. Ring, MD, PhD – Yale University School of Medicine
4:20 p.m. Tumor-targeted Delivery of Immunostimulatory Cytokine/Antibody Fusion Proteins
Jamie Spangler, PhD – Johns Hopkins
4:40 p.m. no_symbol.pngNew Data on IL-18, an Innate Cytokine
Aaron Ring, MD, PhD – Yale School of Medicine
5 p.m. no_symbol.pngBlocking Inhibitory Roles of Interferon and Improving Response to Anti-PD1 with JAK Inhibitors
Andy Minn, MD, PhD – University of Pennsylvania
5:20 p.m. no_symbol.png(657) NT-I7, a long-acting IL-7, plus pembrolizumab favors CD8 T-cell infiltration in liver metastases of heavily pre-treated, immunologically cold, MSS-colorectal and pancreatic cancer
Aung Naing, MD – MD Anderson Cancer Center

Concurrent Session 214

4:20–5:35 P.M. EST

Abstract Session

Location: 153ABC
Chair:
Sumit Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center

4:20 p.m.

(1133) Remodeling the immunosuppressive tumor microenvironment with oncolytic virus-mediated delivery of a potent TGF-b inhibitor
Kristin DePeaux, BS – University of Pittsburgh

4:35 p.m.

(1307) The microbiome-derived metabolite TMAO drives immune activation and boosts response to immune checkpoint blockade in pancreatic cancer
Gauri Mirji, PhD – Wistar Institute

4:50 p.m.

no_symbol.png(528) Acquired resistance to PD-(L)1 blockade in patients with non-small cell lung cancer (NSCLC)
Biagio Ricciuti, MD – Dana-Farber Cancer Institute

5:05 p.m.

(607) MCGRAW Trial: Evaluation of the safety and efficacy of an oral microbiome intervention (SER-401) in combination with nivolumab in first line metastatic melanoma patients
Isabella Glitza Oliva, MD, PhD – The University of Texas MD Anderson Cancer Center

5:20 p.m.

(482) ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking 'don't-eat-me' signal
Jay Mei, MD, PhD – Antengene Corporation Co., Ltd

5:35–5:40 p.m. EST

Break

Session 215

5:40–6:25 P.M. EST

Poster Symposium

Location: Ballroom East
Co-Chairs:
Allison Betof Warner, MD, PhD – Memorial Sloan Kettering Cancer Center
Omid Hamid, MD – The Angeles Clinic and Research Institute

5:40 p.m.

(506) FcγRIIB expressed on CD8 T cells limits responsiveness to PD-1 checkpoint inhibition in cancer
Kelsey Bennion, BS – Emory University

5:50 p.m.

(944) Targeting of Notch ligand Jagged2 in lung cancer cells drives anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages
Darwin Chang – Moffitt Cancer Center

6 p.m.

(212) Adoptively transferred Th17 cells cooperate with host B cells to mediate robust immunity to tumors  
Anna Cole, BA – Emory University

6:10 p.m.

no_symbol.png(514) Tumor context dictates reliance on TCF1 for response to immunotherapy
Giulia Escobar, PhD – Brigham and Women's Hospital and Harvard Medical School

Concurrent Session 216

5:40–6:25 P.M. EST

Convergence Towards Enhanced Immunotherapy
Organized in collaboration with Stand Up To Cancer (SU2C)

Location: Hall B2
Co-Chairs:
James L. Gulley, MD PhD, FACP – National Cancer Institute
Phillip A Sharp, PhD – Koch Institute for Integrative Cancer Research, MIT
5:40 p.m. no_symbol.pngComputational Deconstruction of Neoantigen-TCR Degeneracy for Cancer Immunotherapy
Benjamin D. Greenbaum, PhD – Memorial Sloan Kettering Cancer Center
Vinod Balachandran, MD – Memorial Sloan Kettering Cancer Center
5:55 p.m. Connecting Immune Health and Tumor Biology in Gynecologic Cancers
Claire Friedman, MD – Memorial Sloan Kettering Cancer Center
6:10 p.m. Chimeric Antigen Receptor T-cell (CAR T) Therapy for Pancreatic Cancer
Charly Good, PhD – University of Pennsylvania

6:25–6:30 p.m. EST

Break

6:30–7 P.M. EST

Awards Ceremony

Location: Hall B2
Chair:
Patrick Hwu, MD – Moffitt Cancer Center

 

 Award Ceremony
  • Young Investigator Awards
  • Martin "Mac" Cheever Excellence in Clinical Trial Design - Travel Award
  • SITC Fellowship and Technology Awards
  • Connect-a-Colleague Top Referrer
  • Sparkathon Class of 2022 Recognition
  • Presidential Travel Awards
  • Presidential Award

7–8:30 P.M. EST

Poster Reception and JITC 10th Anniversary Celebration Reception*

Location: Hall C 

 

*JITC 10th Anniversary Celebration Reception

Similar to the immunotherapy field as a whole, JITC has experienced tremendous evolution and growth over the past decade. Join JITC editors, reviewers, authors, and readers in celebrating major accomplishments in the journal and in the field over the past ten years.

 

7–8:30 P.M. EST

Poster Reception and Networking Event for URMs in STEM and Early Career Scientists

Location: The Node, the Early Career Scientist Lounge Area, in the middle of the Hall C (BCEC)

8:30–11:30 P.M. EST

The CheckPoints Party

Location: Omni Boston Hotel at the Seaport, Momentum Ballroom

Saturday, Nov. 12, 2022

37th Annual Meeting

Boston Convention & Exhibition Center

8 a.m.–1:05 p.m. EST

Times and program schedules subject to change.

Download Annual Meeting Schedule >

no_symbol.png Indicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.

Session 300

8–8:05 A.M. EST

Organizer Welcome

Location: Hall B2
Chair:

Session 301

8:05–9:45 A.M. EST

Resistance to Checkpoint Blockade Immunotherapy

Location: Hall B2
Co-Chairs:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
Alexandra Snyder, MD – Generate Biomedicines
8:05 a.m. no_symbol.pngIntroduction
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
8:10 a.m. no_symbol.pngMyeloid Cells; Angiogenesis and Hypoxia
Stefani Spranger, PhD – Ludwig Center – Massachusetts Institute of Technology

8:35 a.m. Patterns of Progression and Response: Tumor Dynamics in Patients Treated with CPI Beyond Progression
Alexandra Snyder, MD – Generate Biomedicines
9 a.m. no_symbol.png(1450) TGβ-dependent LRRC15+ myofibroblasts dictate the tumor fibroblast setpoint to promote cancer immunotherapy resistance
Akshay Krishnamurty, PhD – Genentech

9:15 a.m. no_symbol.pngModels and Mechanisms of Resistance to Immune Checkpoint Blockade in Lung Cancer
Katerina Politi, PhD – Yale School of Medicine

9:40 a.m. no_symbol.pngClosing Remarks
Alexandra Snyder, MD – Generate Biomedicines

9:45–9:55 A.M. EST

Break

Session 302

9:55–11:25 A.M. EST

Thomas Waldmann Memorial Plenary Session: New Immunotherapies

Location: Hall B2
Co-Chairs:
Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center
Ryan J. Sullivan, MD – Harvard Medical School, Massachusetts General Hospital
9:55 a.m. no_symbol.pngIntroduction
Ryan J. Sullivan, MD – Harvard Medical School, Massachusetts General Hospital
10 a.m. no_symbol.pngLAG-3: The Third Checkpoint Inhibitor
Dario Vignali, PhD – University of Pittsburgh School of Medicine

10:20 a.m. no_symbol.pngLibrary-based Approaches to Detect and Reprogram Immunity
Michael Birnbaum, PhD – Massachusetts Institute of Technology
10:40 a.m. no_symbol.png(778) Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in 'cold' and I-O refractory metastatic solid tumors
Breelyn Wilky, MD – University of Colorado Cancer Center
10:50 a.m. (1329) Ultra-pH sensitive nanoparticles increase therapeutic index of IL-2-Fc
Qiang Feng, PhD – University of Texas Southwestern Medical Center
11 a.m. no_symbol.pngQuestion and Answer
Dario Vignali, PhD – University of Pittsburgh School of Medicine
Michael Birnbaum, PhD – Massachusetts Institute of Technology
Breelyn Wilky, MD – University of Colorado Cancer Center
Qiang Feng, PhD – University of Texas Southwestern Medical Center
11:25 p.m. no_symbol.pngClosing Remarks
Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center

11:25–11:35 A.M. EST

Break

Session 303

11:35–1:05 P.M. EST

Hot Topic Symposium: When Phase III Trial Results Diverge from Phase II Data – An Analysis of Recent Trials in Immuno-Oncology

Location: Hall B2
Co-Chairs:
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer Center

11:35 a.m.

Melanoma Failed CPI Trials (IDO, TVEC, BEMPEG, Idura, Combi I, IMSpire)
Adil Daud, MD – University of California, San Francisco

11:55 a.m.

no_symbol.pngNSCLCA Trials
Roy Herbst, MD, PhD – Yale Cancer Center

12:15 p.m.

Cellular Therapy
John Haanen, MD, PhD – Netherlands Cancer Institute

12:35 p.m.

no_symbol.pngSITC Checklist: decision to proceeed to phase III
Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer Center

12:50 p.m.

no_symbol.pngPanel Discussion
Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer Center
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
Adil Daud, MD – University of California, San Francisco
Roy Herbst, MD, PhD – Yale Cancer Center
John Haanen, MD, PhD – Netherlands Cancer Institute